Drugs / ACM-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05385991 | Jul 2022 → Jun 2023 | COVID-19 | ACM Biolabs | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-09-07 | Actimed Therapeutics Ltd | Regulatory Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia actimedtherapeutics.com ↗ |
| 2023-09-05 | ACM Biolabs | Results ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001 acmbiolabs.com ↗
ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data |
| 2022-03-04 | ACM Biolabs | Results ACM Biolabs’ intranasaler COVID-Impfstoff zeigt herausragende präklinische Ergebnisse mit breitem Schutz gegen verschiedene Virusvarianten einschliesslich Omicron acmbiolabs.com ↗
Nachdem ACM-001, ein SARS-CoV-2-Spike-Protein-Impfstoff (Beta-Variante) kombiniert mit einem Adjuvans, erfolgreich alle präklinischen Sicherheitstests erfüllt hat, kann diese Vakzine der zweiten Generation in Kürze die klinische Entwicklung starten. |
| 2022-03-04 | ACM Biolabs | Results ACM Biolabs’ intranasal COVID vaccine presents excellent preclinical results with broad protection against Variants of Concerns including Omicron acmbiolabs.com ↗
ACM Biolabs, a Singaporean-Swiss biotechnology company focusing on the development of prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, today announced that its first clinical candidate vaccine, ACM-001, a 2nd generation COVID vaccine, demonstrated broad protection against variants of concerns, including delta and omicron in a variety of preclinical studies. |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05385991 ↗ |
| Known as | ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate | “ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)” NCT05385991 ↗ |
| Modality | Vaccine | “ACM-001 is developed as a booster vaccine against SARS-CoV-2” NCT05385991 ↗ |
| Route | Intramuscular | “Participants of cohorts 1,3,5 and 7 will receive an IM injection into the deltoid region” NCT05385991 ↗ |